Free Republic

Yale University announced it will now require students to get a bivalent COVID-19 vaccine booster by the start of the 2023 spring semester. “Based on recent CDC recommendations, the university will require all undergraduate, graduate, and professional students—other than those with an approved medical or religious exemption—to receive an updated, bivalent COVID-19 vaccine booster by the start of the spring semester, even if they have previously received a monovalent booster,” Stephanie Spangler, Vice Provost for Health Affairs and Academic Integrity, wrote in a message to the Yale Community. She explained that the booster is necessary because “experience and research have...

Few people have received updated COVID-19 vaccine boosters since it was first made available in August, according to recent data published by the federal government. About 14.8 million have received bivalent boosters made by Pfizer and Moderna, Centers for Disease Control and Prevention data that was published Thursday shows. The Food and Drug Administration provided emergency use authorizations for both booster doses on Aug. 31 for people aged 12 and older, while it signed off on an emergency approval for children aged 5 to 11 this week. Some 226 million people have received their primary vaccination series, CDC data shows....

(CNN)Using the Johnson & Johnson vaccine as a booster for people initially immunized with the Pfizer/BioNTech vaccine produces a strong immune response and may do more to elicit protection against severe disease, researchers reported Sunday. Their small study of 65 volunteers who all initially got two doses of Pfizer/BioNTech's vaccine showed that using the J&J Janssen vaccine as a booster produced a slower but more sustained antibody response against the original strain of the virus, as well as the Delta and Beta variants, they said.... ...after four weeks, antibody levels began to drop off in people who got boosted with...

A source close to California Gov. Gavin Newsom today told The Defender the governor experienced an adverse reaction to the Moderna COVID vaccine he received Oct. 27. The source, who asked not to be identified, said Newsom’s symptoms were similar to those associated with Guillain–Barré syndrome (GBS), a known side effect of many vaccines. GBS is a neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system — the network of nerves located outside of the brain and spinal cord — and can range from a very mild case with brief weakness to paralysis...

They say he has personal issues to attend to... like half his face is paralyzed. It's likely vaccine-induced Bell's Palsy or Guillain-Barre syndrome. That's why NO ONE is allowed to SEE him. Get it? It’s been rumored that Gavin Newsom is out of sight since getting his booster because he developed Bell’s Palsy or Guillain-Barre Syndrome (GBS). This normally would happen within hours after getting his booster so this make perfect sense. This also explains why nobody has seen him in public since Oct 27: anyone who saw him would instantly know. I checked into this and I’m over 90%...

California Governor Gavin Newsom’s health condition. He reportedly developed symptoms of Bell’s Palsy immediately after getting injected with the Moderna Covid-19 booster shot and has had trouble speaking coherently.

FDA's Marion Gruber and Phil Krause argued current evidence doesn't indicate a need for booster shots among most Americans Available evidence doesn’t yet indicate a need for COVID-19 vaccine booster shots among the general population, an international group of scientists said Monday, including two senior FDA officials reportedly stepping down from their posts over a disagreement with the White House on the administration of booster shots. Marion Gruber, director of the FDA’s Office of Vaccines Research and Review, and her deputy director, Phil Krause, set to leave in October and November, published a viewpoint in The Lancet on Monday along...

Participants in Phase 2 study were tested for pseudovirus neutralization (PsVN) titers prior to boosting approximately 6 to 8 months after their primary vaccination series. Although titers versus the wild-type SARS-CoV-2 virus remained high, with 37 of 40 participants having detectable titers, titers against the variants of concern (B.1.351 and P.1) were much lower, with approximately half of participants having titers below the assay limit of quantification prior to boosting. Two weeks after receiving either mRNA-1273 or mRNA-1273.351, PsVN titers were boosted in all participants and all variants tested. Following boost, geometric mean titers (GMT) against the wild-type, B.1.351, and...